Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice

[1] Lieberman JA(2005)Effectiveness of antipsychotic drugs in patients with chronic acizophrenia N Engl J Med 353 1209-1223

[2] Stroup TS(2013)World federation of societies of biological psychiatry (wfsbp) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects World J Biol Psychiatry 14 2-44

[3] McEvoy JP(2008)Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia Patient Prefer Adherence 26 S48-S54

[4] Hasan A(2020)Unmet medical needs and other challenges in the treatment of patients with schizophrenia Am J Manag Care 82 MY20096AH1C-125

[5] Falkai P(2021)Treatment-resistant schizophrenia: definition, predictors, and therapy options J Clin Psychiatry 8 117-820

[6] Wobrock T(2018)A prospective year-long follow-up of lurasidone use in clinical practice: factors predicting treatment persistence Ther Adv Psychopharmacol 33 813-942

[7] Lieberman J(2017)Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis Curr Med Res Opin 174 927-176

[8] Glenthoj B(2017)Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors Am J Psychiatry 27 165-undefined

[9] Gattaz WF(2012)Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study Int Clin Psychopharmacol undefined undefined-undefined

[10] Ascher-Svanum H(undefined)undefined undefined undefined undefined-undefined

[1] Lieberman JA(2005)Effectiveness of antipsychotic drugs in patients with chronic acizophrenia N Engl J Med 353 1209-1223

[2] Stroup TS(2013)World federation of societies of biological psychiatry (wfsbp) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects World J Biol Psychiatry 14 2-44

[3] McEvoy JP(2008)Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia Patient Prefer Adherence 26 S48-S54

[4] Hasan A(2020)Unmet medical needs and other challenges in the treatment of patients with schizophrenia Am J Manag Care 82 MY20096AH1C-125

[5] Falkai P(2021)Treatment-resistant schizophrenia: definition, predictors, and therapy options J Clin Psychiatry 8 117-820

[6] Wobrock T(2018)A prospective year-long follow-up of lurasidone use in clinical practice: factors predicting treatment persistence Ther Adv Psychopharmacol 33 813-942

[7] Lieberman J(2017)Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis Curr Med Res Opin 174 927-176

[8] Glenthoj B(2017)Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors Am J Psychiatry 27 165-undefined

[9] Gattaz WF(2012)Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study Int Clin Psychopharmacol undefined undefined-undefined

[10] Ascher-Svanum H(undefined)undefined undefined undefined undefined-undefined